Ensign Peak Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-7,577
| Closed | -$200K | – | 2272 |
|
|
2022
Q3 | $200K | Sell |
7,577
-950
| -11% | -$25.1K | ﹤0.01% | 1877 |
|
|
2022
Q2 | $379K | Hold |
8,527
| – | – | ﹤0.01% | 1576 |
|
|
2022
Q1 | $422K | Hold |
8,527
| – | – | ﹤0.01% | 1624 |
|
|
2021
Q4 | $434K | Sell |
8,527
-8,390
| -50% | -$427K | ﹤0.01% | 1674 |
|
|
2021
Q3 | $944K | Hold |
16,917
| – | – | ﹤0.01% | 1455 |
|
|
2021
Q2 | $724K | Buy |
16,917
+3,200
| +23% | +$137K | ﹤0.01% | 1521 |
|
|
2021
Q1 | $573K | Buy |
13,717
+1,500
| +12% | +$62.7K | ﹤0.01% | 1581 |
|
|
2020
Q4 | $569K | Hold |
12,217
| – | – | ﹤0.01% | 1578 |
|
|
2020
Q3 | $519K | Hold |
12,217
| – | – | ﹤0.01% | 1524 |
|
|
2020
Q2 | $586K | Hold |
12,217
| – | – | ﹤0.01% | 1429 |
|
|
2020
Q1 | $562K | Buy |
12,217
+400
| +3% | +$18.4K | ﹤0.01% | 1363 |
|
|
2019
Q4 | $710K | Buy |
+11,817
| New | +$710K | ﹤0.01% | 1447 |
|